Univercells

Avenue de Tervueren 270
1150 Brussel (Sint-Pieters-Woluwe)
BE
Univercells
Foundation date
23/01/2013
Sector
#Biotechnology - otherSubsector
- #Therapeutics - Peptides
- #Therapeutics - Proteins
- #Therapeutics - Small molecules
- #Therapeutics - Vaccines
- #Other - Industrial Biotechnology
- #Pharma - Nucleic acid drugs
Therapeutic areas
- #Cardiovascular
- #Conditions originating in the perinatal period
- #Digestive system
- #Neoplasms / cancer / oncology
- #Respiratory system
- #Skin and subcutaneous tissue
Univercells is a global life science s company that makes biologics available to all. Leveraging our core strengths in scaling, production, and bioprocessing, we build businesses and find new ways to support access to medicines and promote sustainability. Through entrepreneurship and technology-driven affordability, we address the needs of the entire health value chain.Univercells is headquartered in Gosselies and benefits from the support of regional and national investors, as well as international investors, such as the Bill & Melinda Gates Foundation, EIB, Global Health Investment Fund, among others active in the health and vaccine industry.
Upcoming events
All events-
2809 '22
NLSDays 2022
Event by: SwedenBIO -
2405 '22
PrecisionMed Expo & Summit
Event by: Smart Planet Media International -
2405 '22
EMERGE GHI
Event by: Smart Planet Media International
Latest news
More news-
Latest field trials validate strength of Biotalys’ first biocontrol Evoca
Thursday May 19th 2022
Read more
-
Belgian biotech in European Top-3 despite turbulent times
Wednesday May 18th 2022
Read more
-
KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus
Wednesday May 18th 2022
Read more